Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MYOC | Q99972 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16690170 | 0.88 | MAPK1 (0.53) | MEN1KMT2AMAPK1GAAPOLB | |
| SCHEMBL9962625 | 0.84 | MAPK1 (0.49) | MEN1KMT2AMAPK1GAAMAPT | |
| SCHEMBL9962609 | 0.83 | GAA (0.51) | MEN1KMT2AMAPK1GAAPOLB | |
| SCHEMBL13192526 | 0.81 | XDH (0.47) | MEN1KMT2AMAPK1POLBNPC1 | |
| SCHEMBL267756 | 0.81 | CES1 (0.54) | SRD5A2MEN1KMT2AMAPK1POLB | |
| SCHEMBL27852524 | 0.80 | MAPK1 (0.58) | MEN1KMT2AMAPK1GAANPC1 | |
| SCHEMBL40825 | 0.80 | MAPK1 (0.79) | SRD5A2MEN1KMT2AMAPK1POLB | |
| SCHEMBL5313730 | 0.79 | NPC1 (0.63) | MEN1KMT2AMAPK1GAAPOLB | |
| SCHEMBL5313736 | 0.79 | NPC1 (0.63) | MEN1KMT2AMAPK1GAAPOLB | |
| SCHEMBL17673783 | 0.79 | NPC1 (0.63) | MEN1KMT2AMAPK1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2223910-B1 | OXIME ESTERS AND PHOTOPOLYMERIZATION INITIATORS CONTAINING THE SAME | ADEKA CORP (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8202679-B2 | Oxime ester compound and photopolymerization initiator containing the same | ADEKA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-8202679-B2 | Oxime ester compound and photopolymerization initiator containing the same | ADEKA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20100249262-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME | ADEKA CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249262-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME | ADEKA CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2223910-A1 | OXIME ESTERS AND PHOTOPOLYMERIZATION INITIATORS CONTAINING THE SAME | Adeka Corporation (JP) | 2010-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249262-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME | OXER1, CYP4A11, NR2E3 | SRD5A2 77/4885MEN1 4343/4885KMT2A 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.